1,3-苯并噻唑-5-胺 | 1123-93-9

• 物质功能分类: 生物 - 细胞培养 - 添加剂
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 中文名称: 1,3-苯并噻唑-5-胺
• 中文别名: 5-氨基-1,3-苯并噻唑；5-氨基苯并噻唑
• 英文名称: 5-aminobenzothiazole
• 英文别名: benzo[d]thiazol-5-amine；1,3-benzothiazol-5-amine；5-Aminobenzothiazol；5-Amino-benzthiazol
• CAS: 1123-93-9
• 化学式: C₇H₆N₂S
• mdl: MFCD04115282
• 分子量: 150.204
• InChiKey: UJZYHMZRXGNDFB-UHFFFAOYSA-N

物化性质

• 熔点：
  55 °C
• 沸点：
  323.1±15.0 °C(Predicted)
• 密度：
  1.383

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  67.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• TSCA：
  Yes
• 危险等级：
  IRRITANT
• 危险品标志：
  Xn
• 危险类别码：
  R20/21/22
• 危险品运输编号：
  UN 2811
• 海关编码：
  2934999090
• 危险类别：
  IRRITANT
• 安全说明：
  S22,S26,S36/37/39
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  存放于室温环境中，并请密封保存。

SDS

Name:	1 3-Benzothiazol-5-amine Material Safety Data Sheet
Synonym:	None Known
CAS:	1123-93-9

Section 1 - Chemical Product MSDS Name:1 3-Benzothiazol-5-amine Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
1123-93-9	1,3-Benzothiazol-5-amine	90+	214-381-8

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Clean up spills immediately, observing precautions in the Protective Equipment section. Sweep up or absorb material, then place into a suitable clean, dry, closed container for disposal. Avoid generating dusty conditions. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation. Wash clothing before reuse.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 1123-93-9: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: off-white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 58-61 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C7H6N2S
Molecular Weight: 150.20

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Dust generation.
Incompatibilities with Other Materials:
Oxidizing agents, acids, acid chlorides.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Will not occur.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 1123-93-9 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1,3-Benzothiazol-5-amine - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
IMO
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
RID/ADR
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing group:

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 22 Do not breathe dust.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 1123-93-9: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 1123-93-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 1123-93-9 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1,3-苯并噻唑-5-胺 在 氢溴酸 、 sodium nitrite 、 copper(I) bromide 作用下， 以 水 为溶剂， 反应 5.5h， 生成 5-溴苯并噻唑
  参考文献：
  名称：

  Trifluoromethyl substituted benzamides as kinase inhibitors

  摘要：

  该发明涉及公式I的三氟甲基取代苯甲酰胺化合物，包括这些化合物的药物，其作为药物或用于制造药物的用途，特别是作为蛋白激酶抑制剂，特别是作为ephrin受体激酶的抑制剂，和/或用于治疗由蛋白激酶活性介导的疾病状态、紊乱或疾病的方法，包括给予这些化合物的治疗方法，特别是治疗和预防治疗的方法，以及化合物的制造方法和用于它们合成的新型中间体和部分步骤。

  公开号：

  US20060035897A1
• 作为产物：
  描述：

  N-(2-溴-5-硝基苯基)甲酰胺 在 sodiumsulfide nonahydrate 、 铁粉 、 氯化铵 、 sulfur 作用下， 以 乙醇 、 水 为溶剂， 反应 2.5h， 生成 1,3-苯并噻唑-5-胺
  参考文献：
  名称：

  2-Aryl-benzothiazol-5-amines的尿素衍生物：人类非洲锥虫病的新型潜在药物。

  摘要：

  从这个实验中先前的出版物（帕特里克，等。生物有机。医药化学2016，24，2451年至2465年）探索2-（2-苯甲酰氨基）乙基-4-苯基噻唑（的新衍生物的抗锥体虫活动1），被鉴定为对人类非洲锥虫病的病原体布鲁氏锥虫的打击。尽管许多这些化合物，尤其是尿素类似物非常有效，但这些分子总体上表现出较差的代谢稳定性。本工作描述了在分子上不同位置的药物化学优化产生的65种新类似物的合成。最有希望的化合物是2-芳基-苯并噻唑-5-胺的脲衍生物。一种这样的类似物，基于体外活性，代谢稳定性和脑渗透性，选择了S）-2-（3,4-二氟苯基）-5-（3-氟-N-吡咯烷基酰胺基）苯并噻唑（57）进行体内功效研究。该化合物在早期和晚期人类非洲锥虫病的鼠模型中均达到了5/5的治愈率，代表了开发对抗这种被忽视疾病的药物的新先导。

  DOI：

  10.1021/acs.jmedchem.6b01163

文献信息

• [EN] PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS<br/>[FR] PYRROLOTRIAZINES EN TANT QU'INHIBITEURS D'ALK ET DE JAK2
  申请人：CEPHALON INC

  公开号：WO2010071885A1

  公开（公告）日：2010-06-24

  The present invention provides a compound of formula (I) or a salt form thereof, wherein Q1, Q2, Q3, and Q4 are as defined herein. The compound of formula (I) has ALK and/or JAK2 inhibitory activity, and may be used to treat proliferative disorders.

  本发明提供了一种式（I）的化合物或其盐形式，其中Q1、Q2、Q3和Q4如本文所定义。式（I）的化合物具有ALK和/或JAK2抑制活性，并可用于治疗增殖性疾病。
• Fluorosulfonylation of arenediazonium tetrafluoroborates with Na2S2O5 and N-fluorobenzenesulfonimide
  作者：Shuai Liu、Yangen Huang、Xiu-Hua Xu、Feng-Ling Qing

  DOI：10.1016/j.jfluchem.2020.109653

  日期：2020.12

  the three-component reaction of arenediazonium tetrafluoroborates, Na2S2O5, and N-fluorobenzenesulfonimide (NFSI). The reaction proceeds through a radical tandem process, affording various arenesulfonyl fluorides in moderate to high yields. This protocol not only provides a complement to the previous fluorosulfonylation reactions, but also extends the applications of Sandmeyer reaction.

  通过四氟硼酸壬二唑鎓，Na 2 S 2 O 5和N-氟苯磺酰亚胺（NFSI）的三组分反应，实现了无过渡金属的Sandmeyer型氟磺酰化反应。该反应通过自由基串联过程进行，以中等至高产率提供各种芳烃磺酰氟。该方案不仅为以前的氟磺酰化反应提供了补充，而且扩展了桑德迈尔反应的应用。
• [EN] ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE "RIG-I' PATHWAY AND METHODS OF USE THEREOF<br/>[FR] ACTIVATEURS DE LA VOIE DU GÈNE INDUCTIBLE PAR L'ACIDE RÉTINOÏQUE "RIG-I" ET LEURS PROCÉDÉS D'UTILISATION
  申请人：KINETA INC

  公开号：WO2020036574A1

  公开（公告）日：2020-02-20

  The present invention is directed to compounds of Formula (I), which are activators of the RIG-I pathway.

  本发明涉及式(I)化合物，该化合物是RIG-I通路的激活剂。
• ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE "RIG-I" PATHWAY AND METHODS OF USE THEREOF
  申请人：Kineta Immuno-Oncology LLC

  公开号：US20200055871A1

  公开（公告）日：2020-02-20

  The present invention is directed to compounds of Formula (I), which are activators of the RIG-I pathway.

  本发明涉及式（I）化合物，该化合物是RIG-I通路的激活剂。
• [EN] BENZOTHIADIAZINE COMPOUNDS<br/>[FR] COMPOSÉS BENZOTHIADIAZINE
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2017098421A1

  公开（公告）日：2017-06-15

  The invention is directed to substituted benzothiadiazine derivatives. Specifically, the invention is directed to compounds according to Formula (I):wherein R, R1, R2, R3, R4 and R5 are as defined herein. The compounds of the invention are inhibitors of CD73 and can be useful in the treatment of cancer, pre-cancerous syndromes and diseases associated with CD73 inhibition, such as AIDS, autoimmune diseases, infections, atherosclerosis, and ischemia-reperfusion injury. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting CD73 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  本发明涉及取代苯并噻二嗪衍生物。具体而言，本发明涉及式(I)化合物：其中R、R1、R2、R3、R4和R5定义如下。本发明的化合物是CD73的抑制剂，可用于治疗癌症、前癌综合症和与CD73抑制相关的疾病，如艾滋病、自身免疫病、感染、动脉粥样硬化和缺血-再灌注损伤。因此，本发明进一步涉及包含本发明化合物的药物组合物。本发明更进一步的涉及使用本发明化合物或包含本发明化合物的药物组合物抑制CD73活性和治疗相关疾病的方法。